A

50 subjects screened

DBPCFC

3 excluded based on allergy tests to peanut

40 subjects with confirmed peanut allergy

7 excluded based on DBPCFC to peanut

25 with additional food allergies confirmed by DBPCFC

15 without additional food allergy as per DBPCFC

25 subjects started on multiple food OIT

15 subjects started on single food OIT

1 treatment failure: unable to escalate from initial dose (eczema flares)
2 drop-outs: non-compliant with dosing instructions

3 drop-outs: 1 moved away, 2 were non-compliant with dosing instructions

22 subjects completed analyses

12 completed analyses

B

Screening

Desensitization

Maintenance

Baseline Visit:
- DBPCFC
- IgE measurement
- Skin Prick Test

Rapid Desensitization

Dose Escalation Visits

(Dose increases dependent on patient and safety parameters)

0 1 3 5 7 9 46+

Time (week)

Dose (mg)

Day 1: start dose 0.1 mg; max dose 5 mg

Up to 5 allergens: 1:1:1:1:1

4000 mg per allergen